NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Liquidia Corp is a mid cap company (market value between $2 billion and $10 billion) in the Drug Manufacturers - Specialty & Generic industry.
Liquidia Corp commercializes treatments for rare lung and heart diseases. The company generates revenue from YUTREPIA, an inhaled treprostinil powder for these conditions, and from profit-sharing on a generic treprostinil injection marketed by Sandoz. It operates a commercial field force in the United States targeting healthcare providers involved in treating these patient populations.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Liquidia Corp stock.
Slightly overvalued: intrinsic value $31.91 per share, market price $34.13, margin of safety -7.0% (as of 2026-10-19).
Discounting its cash flows at 8.0% (average of 3 methods) values the shares at $31.91; the price of $34.13 is 7% above that value, and 81% of that value comes from beyond year five.
Leak Score: 37/100 on 9 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 84 Drug Manufacturers - Specialty & Generic stocks
12 more in this industry show a wider margin of safety.
LQDA is slightly overvalued (as of the 2026-10-19 close). Discounting its cash flows at 8.0% (average of 3 methods) values the shares at $31.91; the price of $34.13 is 7% above that value, and 81% of that value comes from beyond year five.
$31.91 per share (as of the 2026-10-19 close), against a market price of $34.13. That is a margin of safety of -7.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
37 out of 100, which we rate "On Watch", on 9 of 12 value investing signals.